-
公开(公告)号:EP3827075A1
公开(公告)日:2021-06-02
申请号:EP19841972.3
申请日:2019-07-26
发明人: FAN, Xiaohu , ZHAO, Yuncheng , YU, Dawei , ZHI, Wujinan , WANG, Chenchen , ZHUANG, Qiuchuan , WANG, Pingyan , GUO, Xuanxuan
-
公开(公告)号:EP3411079A1
公开(公告)日:2018-12-12
申请号:EP17746953.3
申请日:2017-01-26
发明人: FAN, Xiaohu , ZHANG, Fangliang , ZHUANG, Qiuchuan , WANG, Pingyan , YU, Jie , HE, Xian , WANG, Lin , HAO, Jiaying , YANG, Lei
CPC分类号: C12N5/0636 , A61K35/17 , A61K39/0011 , A61K2039/505 , A61K2039/507 , A61K2039/5156 , A61K2039/5158 , A61K2039/572 , C07K16/00 , C07K16/2818 , C07K16/2863 , C07K16/32 , C07K2317/73 , C12N5/16 , C12N2501/48 , C12N2501/51 , C12N2510/02 , C12N2740/16043
摘要: Provided are pharmaceutical compositions comprising an engineered mammalian cell comprising a heterologous nucleic acid encoding an immunomodulator. Further provided are methods of treating cancer using the pharmaceutical composition either singly or in combination with other technologies, such as Chimeric Antigen Receptor (CAR) or recombinant T cell receptor (TCR) modified T cell immunotherapy.
-
公开(公告)号:EP4022041A1
公开(公告)日:2022-07-06
申请号:EP20856772.7
申请日:2020-08-28
发明人: FAN, Xiaohu , ZHAO, Yuncheng , WANG, Bing , YU, Dawei , HUANG, Xin , WANG, Pingyan , ZHUANG, Qiuchuan
IPC分类号: C12N5/0783 , C12N15/85 , C12N15/86 , C12N15/49 , A61K35/17
-
公开(公告)号:EP3645574A1
公开(公告)日:2020-05-06
申请号:EP18823268.0
申请日:2018-06-27
发明人: FAN, Xiaohu , ZHUANG, Qiuchuan , YANG, Lei , WANG, Pingyan , LI, Qingyan
IPC分类号: C07K16/46 , C12N15/13 , A61K39/395 , A61P35/00
-
公开(公告)号:EP3564266A1
公开(公告)日:2019-11-06
申请号:EP17889368.1
申请日:2017-12-29
发明人: FAN, Xiaohu , ZHUANG, Qiuchuan , WANG, Pingyan , YANG, Lei , ZHENG, Xiujun , HAO, Jiaying , LIU, Shaobo
摘要: The present invention discloses a novel chimeric antigen receptor and use thereof. Said novel chimeric antigen receptor consists of a signal peptide, an antigen binding domain, a transmembrane region, and an intracellular signal domain, and comprises a 4-1BB signal peptide and/or a 4-1BB molecular transmembrane region. The present invention separates and purifies nucleic acid sequences of a plurality of chimeric antigen receptors, and provides a chimeric antigen receptor and a CAR-T cell which are specific for a CD19 malignant tumor antigen. In the malignant tumor killing test of hematological cell lines, the ability of immune cells to target and recognize tumor cells is significantly enhanced, and the killing activity against tumor cells is also enhanced.
-
公开(公告)号:EP3508504A1
公开(公告)日:2019-07-10
申请号:EP17845522.6
申请日:2017-08-31
发明人: ZHUANG, Qiuchuan , FAN, Xiaohu , YANG, Lei , WANG, Pingyan
摘要: The present invention relates to a human CD123-targeting chimeric receptor ligand, comprising an IL-3 molecule-based CD123 binding domain, a transmembrane region, and an intracellular signaling domain. The present invention provides a T cell modified by the human CD123-targeting chimeric receptor ligand and capable of specifically binding with CD123 on tumor cell surfaces, thereby having specific cytotoxicity on tumor cells. The present invention further relates to an application of the human CD123-targeting chimeric receptor ligand and an immune effector cell thereof in preparing an anti-tumor immunotherapy drug.
-
公开(公告)号:EP4022044A1
公开(公告)日:2022-07-06
申请号:EP20856951.7
申请日:2020-08-28
发明人: FAN, Xiaohu , ZHAO, Yuncheng , WANG, Bing , YU, Dawei , HUANG, Xin , WANG, Pingyan , ZHUANG, Qiuchuan
IPC分类号: C12N5/10 , C12N15/13 , C12N15/62 , A61K39/395 , A61P35/00
-
公开(公告)号:EP3732192A1
公开(公告)日:2020-11-04
申请号:EP18896351.6
申请日:2018-12-28
发明人: FAN, Xiaohu , WANG, Jun , WANG, Pingyan , ZHUANG, Qiuchuan , MA, Lian
IPC分类号: C07K14/725 , C07K14/705 , C12P21/00
-
-
-
-
-
-
-